Durata Therapeutics Reaches New 1-Year High at $17.20 (DRTX)
Durata Therapeutics (NASDAQ:DRTX)’s share price hit a new 52-week high during mid-day trading on Tuesday , AmericanBankingNews.com reports. The company traded as high as $17.20 and last traded at $17.18, with a volume of 440,411 shares trading hands. The stock had previously closed at $16.38.
Several analysts have recently commented on the stock. Analysts at Summer Street initiated coverage on shares of Durata Therapeutics in a research note on Wednesday, April 9th. They set a “buy” rating and a $22.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $20.00 to $21.00 in a research note on Tuesday, April 1st. Finally, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $17.00 to $19.00 in a research note on Tuesday, April 1st. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $18.00.
The stock’s 50-day moving average is $13.78 and its 200-day moving average is $12.71. The company’s market cap is $444.4 million.
Durata Therapeutics (NASDAQ:DRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.42 earnings per share for the current fiscal year.
In other Durata Therapeutics news, Director Schutter Richard De bought 15,000 shares of the company’s stock on the open market in a transaction dated Monday, May 12th. The stock was purchased at an average price of $15.57 per share, for a total transaction of $233,550.00. Following the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $233,550. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.